A visceral-fat-targeted stack built on tesamorelin, the GHRH analogue FDA-approved for reducing visceral adipose tissue.
Tesamorelin is unique here: it's a GHRH analogue with an actual FDA approval for reducing visceral adipose tissue (in HIV-associated lipodystrophy), and the visceral-fat effect is the best-evidenced of any compound on the site for that specific endpoint.
It's dosed daily, evening-preferred to align with GH rhythm. 5-Amino-1MQ is an optional metabolic add-on. Visceral fat is the metabolically dangerous kind, so this stack has a clearer health rationale than cosmetic fat loss.
| Compound | Role | Dose | Frequency |
|---|---|---|---|
| Tesamorelin GHRH analogue; FDA-approved for visceral fat. | Primary | 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) | Once daily (evening preferred for GH rhythm) |
| 5-Amino-1MQ Optional NNMT-inhibitor metabolic add-on. | Optional | 50-100mg oral or 150-500mcg SubQ | Once daily, preferably morning |